Evaluating the optimal treatment strategy for early and advanced remnant gastric cancer

ANZ J Surg. 2022 Nov;92(11):2907-2914. doi: 10.1111/ans.18049. Epub 2022 Sep 19.

Abstract

Background: This study assessed lymph node metastasis characteristics to investigate the optimal treatment strategy for early and advanced remnant gastric cancer (RGC).

Methods: Cases of completion gastrectomy for RGC were enrolled. The frequency of lymph node metastasis was investigated, and risk factors for metastasis were identified. The clinical significance of completion gastrectomy in early remnant gastric carcinoma cases was also examined. In advanced cases, 3-year survival was analysed to investigate the prognostic importance of lymph node dissection and splenectomy.

Results: Seventy-nine patients were included. Lymphatic invasion and pathological tumour depth were identified as risk factors for lymph node metastasis. There was no metastasis in the pT1 cases. In advanced cases, the incidence of lymph node #10 and jejunal lymph node metastasis was 8.3-10.0% and 17.6%, respectively. Prognosis was found to be unrelated with splenectomy.

Conclusions: Lymphatic invasion and pathological T status were identified as risk factors for LN metastasis in RGC. Additional gastrectomy after ESD might not be mandatory for early RGC cases. For advanced RGC cases, splenectomy might not improve patient prognosis, however, lymph node dissection of jejunal and #10 lymph nodes should be considered due to its high incidence of metastasis.

Keywords: lymph nodes; metastasis; prognosis; remnant gastric cancer; splenectomy; treatment.

MeSH terms

  • Gastrectomy
  • Humans
  • Lymph Node Excision
  • Lymph Nodes / pathology
  • Lymphatic Metastasis / pathology
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Stomach Neoplasms* / pathology